Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment
- PMID: 8487154
- DOI: 10.1515/jpme.1993.21.1.69
Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment
Abstract
Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment. Arterial blood gas analysis was performed at delivery from the clamped cord. Neonatal blood pressure, heart rate and axillary temperature were registered 0.5, 2, 6, 12, 24, 36, 48 hours and 3, 4 and 7 days after birth. Respiratory rate was registered at the same intervals until 36 hours after birth. Blood glucose levels were measured 2, 6, 12 and 24 hours after birth. Peripheral blood flow in the calf was measured at 24 hours of age. Gestational age did not differ between the two groups; 36 (27-40) in the labetalol, and 35 (29-37) weeks in the hydralazine group (median and range). Median cord pH was lower, and the number of infants with a cord pH < 7.20 was higher in the hydralazine group. Blood glucose levels were lower in the labetalol group at 6 hours of age (p < 0.05). No other differences were found between the two groups. The conclusion is that no clinical signs of adrenergic blockade have been found at 24 hours of age, and no negative effect of labetalol on the neonatal adaptation compared to hydralazine antihypertensive treatment was found.
Similar articles
-
Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants.Acta Obstet Gynecol Scand. 1993 Nov;72(8):611-5. doi: 10.3109/00016349309021152. Acta Obstet Gynecol Scand. 1993. PMID: 8259746 Clinical Trial.
-
Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.Hypertens Pregnancy. 2016;35(1):123-8. doi: 10.3109/10641955.2015.1117098. Epub 2016 Feb 24. Hypertens Pregnancy. 2016. PMID: 26910380
-
Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women.Afr Health Sci. 2023 Mar;23(1):320-325. doi: 10.4314/ahs.v23i1.34. Afr Health Sci. 2023. PMID: 37545898 Free PMC article.
-
Fatal hepatotoxicity induced by hydralazine or labetalol.Pharmacotherapy. 1991;11(5):415-8. Pharmacotherapy. 1991. PMID: 1745625 Review.
-
Pathophysiology and Current Clinical Management of Preeclampsia.Curr Hypertens Rep. 2017 Aug;19(8):61. doi: 10.1007/s11906-017-0757-7. Curr Hypertens Rep. 2017. PMID: 28689331 Free PMC article. Review.
Cited by
-
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.Cochrane Database Syst Rev. 2018 Oct 1;10(10):CD002252. doi: 10.1002/14651858.CD002252.pub4. Cochrane Database Syst Rev. 2018. PMID: 30277556 Free PMC article.
-
Drugs for treatment of very high blood pressure during pregnancy.Cochrane Database Syst Rev. 2013 Jul 31;2013(7):CD001449. doi: 10.1002/14651858.CD001449.pub3. Cochrane Database Syst Rev. 2013. PMID: 23900968 Free PMC article.
-
Fortnightly review: management of hypertension in pregnancy.BMJ. 1999 May 15;318(7194):1332-6. doi: 10.1136/bmj.318.7194.1332. BMJ. 1999. PMID: 10323823 Free PMC article. Review. No abstract available.
-
Oral beta-blockers for mild to moderate hypertension during pregnancy.Cochrane Database Syst Rev. 2000;2003(4):CD002863. doi: 10.1002/14651858.CD002863. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2003;(3):CD002863. doi: 10.1002/14651858.CD002863. PMID: 11034777 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources